The Recall Desk
ModerateFDA (Drugs)·D-0172-2021·Announced 2020-12-30

Fresenius Kabi Recalls Sensorcaine Due to Low Epinephrine Levels

Fresenius Kabi is recalling 4,411 trays of Sensorcaine (Bupivacaine HCl and Epinephrine) because the epinephrine component tested below specification.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity rating involving a subpotent drug.

Plain-English summary

Fresenius Kabi USA, LLC is recalling 4,411 trays of Sensorcaine (Bupivacaine Hydrochloride and Epinephrine Bitartrate) 0.5% injection. The product is identified by Batch # 6123760 with an expiration date of 02/2022. The recall was initiated because the epinephrine component produced low out-of-specification assay results, meaning the drug is subpotent.

The affected product is packaged as 25 single-dose vials per tray (NDC 63323-462-37) and was distributed nationwide in the USA. Sensorcaine is a prescription-only medication used for epidural and retrobulbar routes.

Healthcare providers and patients should stop using the affected product and contact Fresenius Kabi for further instructions or a replacement.

The recalled product

Product
SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE)
Brand
SENSORCAINE
Affected units
4,411

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Batch # 6123760
  • Exp 02/2022

Distribution

Distributed nationwide across the United States.

Same manufacturer · Fresenius Kabi USA, LLC

See all →